Within 1 year of initiating a subcutaneous biologic, 54.8% of patients with PsA remained on their index biologic, 18.5% switched from their index biologic to a new therapy, and 26.7% discontinued their index biologic.

Compared with non-switchers, switchers had higher total all-cause healthcare costs, which were driven by increased prescription and medical costs; discontinuers had lower all-cause healthcare costs but the highest medical costs, potentially due to active disease.

Switchers and discontinuers had increased healthcare resource utilization (outpatient visits) than non-switchers.